Drugs targeting atrial‐specific ion channels, Kv1. 5 or Kir3. 1/3.4, are being developed as
new therapeutic strategies for atrial fibrillation. However, current preclinical studies carried …

Human-induced pluripotent stem cell cardiomyocytes (hiPSC-CMs) are a potential source to
develop assays for predictive electrophysiological safety screening. Published studies show …

To assess the utility of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-
CMs) as an in vitro proarrhythmia model, we evaluated the concentration dependence and …

Cardiomyocytes (CMs) generated from human induced pluripotent stem cells (hiPSCs) are
under investigation for their suitability as human models in preclinical drug development …

Background and Purpose Two new technologies are likely to revolutionize cardiac safety
and drug development: in vitro experiments on human‐induced pluripotent stem cell …

Aims Atrial fibrillation (AF) is associated with tachycardia-induced cellular electrophysiology
alterations which promote AF chronification and treatment resistance. Development of novel …

Cardiomyocytes derived from human induced pluripotent stem cells (hiPS-CMs) hold great
promise for development of in vitro research tools to assess cardiotoxicity, including QT …

Most existing culture media for cardiac differentiation of human pluripotent stem cells
(hPSCs) contain significant amounts of albumin. For clinical transplantation applications of …

Developing effective drug therapies for arrhythmic diseases is hampered by the fact that the
same drug can work well in some individuals but not in others. Human induced pluripotent …

Nonclinical studies of drug effects with human induced pluripotent stem cell-derived
cardiomyocytes (hiPSC-CMs) provide new possibilities for evaluating drug safety and …